ORLANDO, FL USA (UroToday.com) - Dr. Neal Shore presented an abstract on a multi-institutional study evaluating the safety and tolerability of long-term treatment (≥ 24 months) and also reported on the efficacy at 56% overall survival (OS) events of study COU-AA-302. In study COU-AA-302, 1 088 patients were randomized 1:1 to abiraterone (AA) 1000 mg + prednisone (P) 5 mg po BID vs placebo + P. “Co-primary” end points were radiographic progression-free survival (rPFS) and OS. Kaplan-Meier was used to estimate the 95% confidence interval (CI) of the end points and median times. Moreover, efficacy analysis and post hoc analysis of adverse events (AEs) was performed at the pre-specified third interim analysis (IA3).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
At IA3, the median follow-up was 27.1 months. rPFS, (HR=0.53 [95% CI], (0.45-0.62), p < 0.0001), and OS (HR=0.79 [95%CI], (0.66-0.96), p = 0.0151), were improved over P; the latter did not reach the pre-specified efficacy boundary (p = 0.0035). All reported secondary end points favored the AA arm of the study. In regards to adverse effects, grade 3/4 AEs (AA + P vs P) were reported as: hypokalemia (3% vs 2%); hypertension (4% vs 3%); increase in alanine aminotransferase (6% vs 1%); and also increase in aspartate aminotransferase (3% vs 1%). Dr. Shore showed the date illustrating that prolonged exposure to AA + P was safe and well tolerated vs P alone among most men. Moreover AA + P did not clinically show any relevant increase in the incidence rate of grade 3/4 AEs with ≥ 24 months drug exposure. The percentage of patients who came off the study due to an AE was reported as 8% (AA) vs 6% (P).
Abiraterone acetate is a selective androgen biosynthesis inhibitor that prolongs OS in patients with mCRPC and is approved for use in this population. This study shows that the updated IA3 of COU-AA-302 causes delay in progression and prolongation of life with a favorable safety profile, including patients who were treated for more than 24 months with AA + P or P.
Presented by Neal D. Shore, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA
Myrtle Beach, SC USA
Written by Reza Mehrazin, MD, medical writer for UroToday.com